These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38226317)

  • 1. A novel combination treatment for fragile X syndrome predicted using computational methods.
    Chadwick W; Angulo-Herrera I; Cogram P; Deacon RJM; Mason DJ; Brown D; Roberts I; O'Donovan DJ; Tranfaglia MR; Guilliams T; Thompson NT
    Brain Commun; 2024; 6(1):fcad353. PubMed ID: 38226317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study.
    Budimirovic DB; Dominick KC; Gabis LV; Adams M; Adera M; Huang L; Ventola P; Tartaglia NR; Berry-Kravis E
    Front Pharmacol; 2021; 12():757825. PubMed ID: 34690787
    [No Abstract]   [Full Text] [Related]  

  • 3. Gaboxadol Normalizes Behavioral Abnormalities in a Mouse Model of Fragile X Syndrome.
    Cogram P; Deacon RMJ; Warner-Schmidt JL; von Schimmelmann MJ; Abrahams BS; During MJ
    Front Behav Neurosci; 2019; 13():141. PubMed ID: 31293404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder.
    Sandhu A; Rawat K; Gautam V; Sharma A; Kumar A; Saha L
    Brain Res; 2023 Sep; 1815():148443. PubMed ID: 37290608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothesis-driven investigations of diverse pharmacological targets in two mouse models of autism.
    Rhine MA; Parrott JM; Schultz MN; Kazdoba TM; Crawley JN
    Autism Res; 2019 Mar; 12(3):401-421. PubMed ID: 30653853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials.
    Braat S; Kooy RF
    Neuropharmacology; 2015 Jan; 88():48-54. PubMed ID: 25016041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
    Lozano R; Hare EB; Hagerman RJ
    Neuropsychiatr Dis Treat; 2014; 10():1769-79. PubMed ID: 25258535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation.
    Oliveros G; Wallace CH; Chaudry O; Liu Q; Qiu Y; Xie L; Rockwell P; Figueiredo-Pereira ME; Serrano PA
    Brain; 2023 Mar; 146(3):898-911. PubMed ID: 35411386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.
    Tsiouris JA; Brown WT
    CNS Drugs; 2004; 18(11):687-703. PubMed ID: 15330685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expressive language abilities of boys with idiopathic autism spectrum disorder and boys with fragile X syndrome + autism spectrum disorder: Cross-context comparisons.
    Hilvert E; Sterling A; Haebig E; Friedman L
    Autism Dev Lang Impair; 2020; 5():2396941520912118. PubMed ID: 36381548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
    Maurin T; Melancia F; Jarjat M; Castro L; Costa L; Delhaye S; Khayachi A; Castagnola S; Mota E; Di Giorgio A; Servadio M; Drozd M; Poupon G; Schiavi S; Sardone L; Azoulay S; Ciranna L; Martin S; Vincent P; Trezza V; Bardoni B
    Cereb Cortex; 2019 Jul; 29(8):3241-3252. PubMed ID: 30137253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Disruption of Metabotropic Glutamate Receptor 5-Homer Interactions Mimics Phenotypes of Fragile X Syndrome in Mice.
    Guo W; Molinaro G; Collins KA; Hays SA; Paylor R; Worley PF; Szumlinski KK; Huber KM
    J Neurosci; 2016 Feb; 36(7):2131-47. PubMed ID: 26888925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome.
    Olmos-Serrano JL; Paluszkiewicz SM; Martin BS; Kaufmann WE; Corbin JG; Huntsman MM
    J Neurosci; 2010 Jul; 30(29):9929-38. PubMed ID: 20660275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D).
    Gurney ME; Cogram P; Deacon RM; Rex C; Tranfaglia M
    Sci Rep; 2017 Nov; 7(1):14653. PubMed ID: 29116166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gaboxadol -- a different hypnotic profile with no tolerance to sleep EEG and sedative effects after repeated daily dosing.
    Ebert B; Anderson NJ; Cremers TI; Rasmussen S; Vogel V; Fahey JM; Sánchez C
    Pharmacol Biochem Behav; 2008 Jul; 90(1):113-22. PubMed ID: 18304623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intellectual functioning and behavioural features associated with mosaicism in fragile X syndrome.
    Baker EK; Arpone M; Vera SA; Bretherton L; Ure A; Kraan CM; Bui M; Ling L; Francis D; Hunter MF; Elliott J; Rogers C; Field MJ; Cohen J; Maria LS; Faundes V; Curotto B; Morales P; Trigo C; Salas I; Alliende AM; Amor DJ; Godler DE
    J Neurodev Disord; 2019 Dec; 11(1):41. PubMed ID: 31878865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.
    Olmos-Serrano JL; Corbin JG; Burns MP
    Dev Neurosci; 2011; 33(5):395-403. PubMed ID: 22067669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman Syndrome.
    Bird LM; Ochoa-Lubinoff C; Tan WH; Heimer G; Melmed RD; Rakhit A; Visootsak J; During MJ; Holcroft C; Burdine RD; Kolevzon A; Thibert RL
    Neurology; 2021 Feb; 96(7):e1024-e1035. PubMed ID: 33443117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy.
    Reyes ST; Deacon RMJ; Guo SG; Altimiras FJ; Castillo JB; van der Wildt B; Morales AP; Park JH; Klamer D; Rosenberg J; Oberman LM; Rebowe N; Sprouse J; Missling CU; McCurdy CR; Cogram P; Kaufmann WE; Chin FT
    Sci Rep; 2021 Aug; 11(1):17150. PubMed ID: 34433831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome.
    Braat S; D'Hulst C; Heulens I; De Rubeis S; Mientjes E; Nelson DL; Willemsen R; Bagni C; Van Dam D; De Deyn PP; Kooy RF
    Cell Cycle; 2015; 14(18):2985-95. PubMed ID: 25790165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.